您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2014, Vol. 52 ›› Issue (11): 45-48.doi: 10.6040/j.issn.1671-7554.0.2014.223

• 临床医学 • 上一篇    下一篇

替罗非班联合IABP对冠脉复杂病变患者PCI术后的近期疗效观察

刘怡   

  1. 徐州市中心医院心内科, 江苏 徐州 221000
  • 收稿日期:2014-04-14 发布日期:2014-11-10
  • 通讯作者: 刘怡.E-mail:yijunliu@126.com E-mail:yijunliu@126.com

Short-term efficacy of tirofiban combined with IABP for patients with complex coronary artery disease after PCI

LIU Yi   

  1. Central Hospital of Xuzhou City, Xuzhou 221000, Jiangsu, China
  • Received:2014-04-14 Published:2014-11-10

摘要: 目的 探讨替罗非班联合主动脉球囊反搏(IABP)对冠脉复杂病变患者行经皮冠状动脉介入治疗(PCI)疗效及预后的影响.方法 回顾性分析2011年1月至2013年12月冠心病有胸痛症状经冠脉造影提示复杂病变并行PCI患者90例,按照PCI术后是否使用替罗非班以及是否应用IABP分为替罗非班组(A组)、替罗非班联合IABP组(B组)和IABP组(C组),每组30例.比较3组临床资料、 血管病变情况、术后心功能指标、出血并发症和血小板减少症的发生率,术后30 d内心血管病事件的发生率等.结果 术后5 d:左室射血分数B组和C组高于A组(P<0.05),BNP值A组明显高于B组和C组(P<0.05).3组间血小板计数差异无统计学意义(P >0.05),B组有1例、C组有2例发生血小板减少,停用肝素及撤离IABP 3 d后,血小板计数恢复正常.总主要心血管事件(MACE)发生率B组显著低于A组和C组(P<0.05).结论 冠脉复杂病变患者于PCI术中早期联合应用替罗非班及主动脉内球囊反搏,有降低PCI术后30 d内MACE事件发生率的趋势,显著改善冠脉血流和心肌灌注并不增加出血风险.

关键词: 经皮冠状动脉介入治疗, 冠脉复杂病变, 替罗非班, 主动脉内球囊反搏, 疗效观察

Abstract: Objective To explore the efficacy and prognosis of tirofiban combined with intra aortic balloon pump (IABP) for patients who had complex coronary artery disease after undergoing percutaneous coronary intervention (PCI). Methods Data of 90 cases of complex coronary artery disease confirmed by coronary angiography who underwent PCI during Jan. 2011 to Dec. 2013 in our hospital were retrospectively analyzed. Patients were divided into three groups: tirofiban group (Group A), tirofiban combined with IABP group (Group B), and IABP group (Group C). The vascular lesions, postoperative cardiac function index, bleeding complications and incidence of thrombocytopenia, and incidence of heart disease 30 days after PCI were compared. Results Five days after PCI, left ventricular ejection time (LVEF) in groups B and C were higher than than that in group A (P<0.05), and the level of BNP was significantly higher in Group A than in groups B and C (P<0.05). Platelet counts showed no significant differences among the three groups (P >0.05). One patient in group B and 2 in group C developed thrombocytopenia, but 3 days after stopping using heparin and withdrawing IABP, the platelet count returned to normal. The incidence of major adverse cardiovascular events (MACE) was significantly lower in group B than in groups A and C. Conclusion During PCI, combining tirofiban and IABP early for patients who had complex lesions can significantly improve coronary blood flowand myocardial perfusion, and reduce the incidence of MACE within 30d without increasing the risk of bleeding.

Key words: Percutaneous coronary intervention, Complex coronary artery lesions, Intra aortic balloon pump, Tirofiban, Observation of curative effect

中图分类号: 

  • R541.4
[1] Ronner E, Boersma E, Akkerhuis K M, et al. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protecttion by a glycoprotein II b/Ill a receptor blocker[J]. Eur Heart J, 2002, 23(3):239-246.
[2] Januzzi J L Jr, Snapinn S M, DiBattiste P M, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) trial[J]. Circulation, 2002, 105(20): 2361-2366.
[3] Talarico G P, Brancati M, Burzotta F, et al. Glycoprotein II B/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the“OPTIMIZE-IT” pilot randomized study[J]. J Cardiovasc Med, 2009, 10(3): 245-251.
[4] 张玉霄, 卢才义, 周圣华, 等. 国产替罗非班对老年急性冠脉综合征介入治疗患者近远期预后的影响[J]. 中国危重病急救医学, 2011, 23(12): 727-730.
[5] Qin T, Xie L, Chen M H. Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon[J]. BMC Cardiovasc Disord, 2013, 13:68. doi: 10.1186/1471-2261-13-68.
[6] Yan H B, Li S Y, Song L, et al. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction[J]. Chin Med J (Engl), 2010, 123(7):877-883.
[7] 荆素敏, 陈魁, 何飞, 等. 替罗非班应用于急性冠状动脉综合征患者不同时机的安全性和有效性[J]. 临床心血管病杂志, 2010, 26(6):468-469.
[8] Stone G W, Olunan E M, Miller M F, et al. Contemporary utilization andotcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry[J]. J Am Coll Cardiol, 2003, 41(11):1940-1945.
[9] Trost J C, Hillis L D. Intra-aortic ballon counterpulsation[J]. Am J Cardiol, 2006, 97(9):1391-1398.
[1] 高远,张海山,郭亮,李玉泽,关启刚,田文,贾志梅,贾大林,张月兰,齐国先,孙英贤 . 替罗非班和磺达肝癸钠联用在急性冠脉综合征中的疗效[J]. 山东大学学报(医学版), 2013, 51(06): 71-74.
[2] 唐振旺. 不稳定型心绞痛介入治疗后基质金属蛋白酶9的表达改变对预后的影响[J]. 山东大学学报(医学版), 2012, 50(2): 120-.
[3] 程义伟1,郝恩魁1,赵卓1,王思思2,杜乃立1,王立启1,王磊1,苏国海1. 替罗非班对急性心梗患者PCI术后左室重构及近期预后的影响[J]. 山东大学学报(医学版), 2010, 48(7): 95-98.
[4] 辛辉1,2,巩会平3,张蕊2,康维强4,葛志明1,张运1. PCI对女性冠心病的临床价值及术前服用β-受体阻滞剂的作用[J]. 山东大学学报(医学版), 2010, 48(4): 98-.
[5] 李媛媛,来庆友,商德亚,刘东兴. 急性心肌梗死急诊介入治疗中替罗非班对冠状动脉内皮细胞功能的影响[J]. 山东大学学报(医学版), 2008, 46(5): 494-497.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!